Drug intelligence / Profile preview

inotuzumab ozogamicin + venetoclax + dexamethasone

Development stage: Unknown
Lead developer: Pfizer
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

A combination therapy consisting of inotuzumab ozogamicin (an antibody-drug conjugate targeting CD22), venetoclax (a BCL-2 inhibitor), and dexamethasone (a corticosteroid). This combination has shown synergistic effects in preclinical studies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The mechanism involves rapid induction of mitochondrial outer membrane permeabilization by venetoclax, DNA damage signaling by inotuzumab ozogamicin, and the anti-inflammatory effects of dexamethasone.

Targets

GR (Glucocorticoid receptor)BCL-2 (BCL-2 family)CD22 (Cluster of Differentiation 22)DNA

Beyond the preview

Go deeper on inotuzumab ozogamicin + venetoclax + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inotuzumab ozogamicin + venetoclax + dexamethasone.

Explore the full profile